🇺🇸 FDA
Pipeline program

LOPERAMIDE , Ultra-Levura 250 mg cápsulas duras, Placebo to Saccharomyces boulardii

BoWell - Sb252

Phase 3 small_molecule active

Quick answer

LOPERAMIDE , Ultra-Levura 250 mg cápsulas duras, Placebo to Saccharomyces boulardii for Non-constipated Irritable Bowel Syndrome (IBS) is a Phase 3 program (small_molecule) at Biocodex with 1 ClinicalTrials.gov record(s).

Program details

Company
Biocodex
Indication
Non-constipated Irritable Bowel Syndrome (IBS)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials